Navigation Links
American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast

WASHINGTON, Sept. 1 /PRNewswire-USNewswire/ -- There has been recent concern that suicide may be a complication of montelukast (Singulair) therapy. Montelukast is a Food and Drug Administration (FDA) approved oral drug that has been prescribed for more than a decade for the treatment of asthma and seasonal allergy symptoms. An independent study sponsored by the American Lung Association has found no evidence of depression or suicide linked to montelukast.

American Lung Association researchers Janet Holbrook, PhD, MPH and Raida Harik-Khan, PhD have re-analyzed data from patients who had participated in past clinical trials involving montelukast conducted by the Association's Asthma Clinical Research Centers (ACRC) Network to identify any signals that might suggest a link between montelukast and its effect on emotional well- being. They report their findings in an upcoming issue of the Journal of Allergy and Clinical Immunology.

"Discovering adverse effects of a drug after it is on the market can be very difficult, because the data are usually gathered from single events reported by doctors, which makes it is challenging to differentiate actual side effects from events unrelated to the drug," said Norman Edelman, MD American Lung Association Chief Medical Officer. "The value of this 'look back' study is that the investigators were able to compare a large group of patients given montelukast with those given a placebo making a firm scientific conclusion possible."

Holbrook and Harik-Khan reviewed quality of life and emotional well being data collected from patients in three American Lung Association ACRC Network clinical trials that had used montelukast as one of their treatments. Of the 1,352 patients who participated in the double-blind, controlled studies, 569 of these patients had been randomly assigned to take montelukast. The researchers analyzed these patients' data and found no evidence of any deterioration of emotional well being in either the adults or the children who received montelukast. On the contrary, the research team found a positive effect on emotional outlook when comparing patients taking montelukast to those receiving placebo.

While the findings of this study are reassuring and produced no evidence to support the recent publicity regarding a link between montelukast and depression or suicide, the authors do not dismiss the possibility that there could be other unrecognized adverse reactions to montelukast.

The ACRC Network is an American Lung Association-sponsored research program that conducts large-scale clinical trials with the mission of advancing the care and treatment of people with asthma. The network, with a central data coordinating center and 20 clinical centers located across the country, is the largest of its kind. By placing its clinical centers around the country, the ACRC Network is able to enroll large numbers of patients for clinical trials, thus ensuring relevant research findings can be interpreted with the highest level of scientific authority.

Norman Edelman, MD disclosed stock ownership with Johnson & Johnson. Janet Holbrook, PhD, MPH made the following disclosures: Research support by Takeda and Astra-Zeneca; Raida Harik-Khan, PhD had no disclosures.

The American Lung Association has a strict policy of not endorsing products. Corporate and educational partnerships affiliated with the Association's National Headquarters can be found online at: nal _Partnerships.htm (due to URL length, please copy and paste into browser).

About the American Lung Association: Beginning our second century, the American Lung Association is the leading organization working to prevent lung disease and promote lung health. Lung disease death rates are currently increasing while other major causes of death are declining. The American Lung Association funds vital research on the causes of and treatments for lung disease. With the generous support of the public, the American Lung Association is "Improving life, one breath at a time." For more information about the American Lung Association, a Charity Navigator Four Star Charity, or to support the work it does, call 1-800-LUNG-USA (1-800-586-4872) or log on to

SOURCE American Lung Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Aspirin Named 8th World Wonder by Majority of Americans
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
7. TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site
8. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
9. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
Post Your Comments:
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... Netherlands has found that immunotherapy can be ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... ProSidebar: Fashion is a set of 30 kinetic edge graphics ... editors can easily add an informative sidebar to any FCPX production. Create lists, ... self-animating drop zones, lines, bars, and text with the ease of FCPX's drag and ...
(Date:11/27/2015)... ... 2015 , ... A simply groundbreaking television series, "Voices in America", which is ... an array of issues that are presently affecting Americans. Dedicated to providing the world ... is changing the subjects consumers focus on, one episode at a time. , ...
(Date:11/27/2015)... IL (PRWEB) , ... November 27, 2015 , ... ... of the largest, most successful and prominent nonprofit healthcare organizations in the country. ... governance involvement with various organizations, and helped advance the healthcare industry as a ...
(Date:11/26/2015)... ... 2015 , ... Patients at Serenity Point Recovery, a holistic ... Thanksgiving Day to share the things that they are most grateful for today. ... channel, patients displayed what they wrote on index cards, describing the things that ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
Breaking Medicine News(10 mins):